The Sarasota-based medical device company is focused on treating infertility with its FDA-cleared INVOcell product.
SARASOTA — INVO Bioscience Inc. has named Inger Britt Carlsson the company's vice president of medical affairs, a newly created position.
The Sarasota-based medical device company is focused on treating infertility with its FDA-cleared INVOcell product, according to a statement.
Carlsson will develop and oversee INVO Bioscience's educational symposiums, generate scientific abstracts and publications on the INVOcell technology and build relationships with opinion leaders around the world, the release states.
Carlsson has over 30 years of experience in the fertility industry. She was most recently global director of medical affairs for CooperSurgical Fertility and Genomics. There she focused on developing and overseeing educational initiatives; overseeing scientific abstracts, publications, research and research collaborations; and building relationships with clinical and research experts.
"Inger Britt has strong knowledge of the worldwide fertility markets having served in a medical affairs capacity for many of the world's leading fertility and women's health companies," says INVO Bioscience CEO Steve Shum in the statement. "As we look to expand the adoption of INVOcell internationally, I am confident her background and experience will benefit us, especially as we look to expand our relationships with key opinion leaders and further highlight the market differentiating attributes of the INVOcell technology to doctors and patients around the world."